Immunomedics Inc

Immunomedics — Investor Day (January 2017)

122 slides from Immunomedics's investor day presentation, Jan 18, 2017

  1. Slide 1: Advanced Antibody-Based Therapeutics: 2017 Investor R&D Day

    IMMUNOMEDICS, INC. Advanced Antibody - Based Therapeutics Oncology Autoimmune Diseases January 2017 2017 Investor R&D Day

  2. Slide 2: Disclaimer

    Disc l aimer 2 Certain statements in this presentation constitute “forward - looking statements” of Immunomedics within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute “forward - looking information” within the meaning of applicable U . S . securities laws . Such s

  3. Slide 3: Important Additional Information

    Important Additional Information 3 Immunomedics, Inc . (the “Company”), its directors and certain of its executive officers are deemed to be participants in the solicitation of proxies from Company stockholders in connection with the matters to be considered at the Company’s 2016 Annual Meeting . Th

  4. Slide 4: Agenda

    A g enda • Opening Remarks: Cynthia L. Sullivan, President and Chief Executive Officer • New Board Member Introductions: Brian A. Markison, Lead Independent Director • Overview of Clinical & Preclinical Programs, Platform Technologies, and Intellectual Property: David M. Goldenberg, Sc.D., M.D., Cha

  5. Slide 5: Opening Remarks

    Opening Remarks Cynthia L. Sullivan, President and Chief Executive Officer 5

  6. Slide 6: Immunomedics – Corporate Information

    Immunomedics – Corporate Information 6 • Clinical - stage biopharmaceutical company – Based in Morris Plains, New Jersey • History of approved products – CEA - Scan®; LeukoScan® • Management Leadership – David M. Goldenberg, ScD, MD, Chairman, Chief Science Officer and Chief Patent Officer – Cynthia

  7. Slide 7: Immunomedics – Corporate Information (Cont'd)

    Immunomedics – Corporate Information (Cont’d) 7 • Committed to be a leading, innovative biopharmaceutical company, dedicated to improving health and quality of life with novel therapeutics for the treatment of cancer, autoimmune and other serious diseases • Focus on developing monoclonal antibody -

  8. Slide 8: Lead Investigational Product – Sacituzumab Govitecan (IMMU-132)

    Lead Investigational Product – Sacituzumab Govitecan (IMMU - 132) 8 • Novel ADC platform which emphasizes a targeted approach with low toxicity • Lead indication - TNBC – Designations include: Breakthrough Therapy and Fast Track – IMMU - 132 also has Fast Track designations in NSCLC and SCLC, and ha

  9. Slide 9: Compound designations, phases and development plans

    C ompoun d Designations Phase 1 Phase 2 Phase 3 Development Plans (Assuming Sufficient Funds) IMMU - 132 (Sacituzumab govitecan) ▪ Breakthrough Therapy, Fast Track ▪ Completed enrollment of 100+ Phase 2 patients in 2016 ▪ Interim data submission and publishing in early 2017 ▪ Validation of commercia

  10. Slide 10: New Board Member Introductions

    New Board Member Introductions Brian A. Markison, Lead Independent Director 10

  11. Slide 11: New Board Members

    New Board Members 11 • Jason Aryeh – Founder & managing general partner, JALAA Equities, LP • Dr. Geoffrey Cox – Principal, Beacon Street Advisors, LLC • Robert Forrester – President & CEO, Verastem, Inc. • Bob Oliver – President & CEO, Otsuka America Pharma, Inc. • New independent directors bring s

  12. Slide 12: Overview of Clinical & Preclinical Programs, Platform Technologies, and IP

    Overview of Clinical & Preclinical Programs, Platform Technologies, and Intellectual Property 12 David M. Goldenberg, Sc.D., M.D., Chairman, Chief Scientific Officer, and Chief Patent Officer

  13. Slide 13: Broad Technology Platforms

    Broad Technology Platforms 13 • Antibody - based technologies, involving – Unconjugated mAbs – Antibody - drug conjugates – Companion ImmunoPET imaging agents (IBC Pharmaceuticals, Inc.) – Bispecific antibodies (DNL®) – T - cell retargeting immuno - oncology • All internal science, with extensive pa

  14. Slide 14: Profile of Major mAbs

    Profile of Major mAbs 14 • Anti - CD22, epratuzumab – oncology and autoimmune disease* • Anti - CD20, veltuzumab – oncology and autoimmune disease* • Anti - CD74, milatuzumab – oncology and autoimmune disease* • Anti - CEACAM5, labetuzumab – oncology* • Anti - MUC5a,c, clivatuzumab – oncology* • Ant

  15. Slide 15: Antibody-Drug Conjugates

    Antibody - Drug Conjugates 15

  16. Slide 16: What Makes IMMU's ADCs Different?

    • Unique approach to ADC therapeutics for cancer – Highly cancer - specific antibodies based on 30 years of experience – Utilize moderately potent payloads: increased therapeutic index • Proprietary linker for rapid payload release at or inside tumor – High drug - to - antibody ratio (~7.6:1) • SN -

  17. Slide 17: What is Sacituzumab Govitecan (IMMU-132)?

    What is Sacituzumab Govitecan (IMMU - 132)? A First - in - Class ADC with a Moderately - toxic Drug 17 • In contrast to other ADCs, IMMU - 132 uses a moderately - toxic drug (SN - 38) at a high drug:antibody ratio (7.6), producing a high therapeutic index • The target: Trop - 2/EGP - 1 is a pan - ep

  18. Slide 18: Novel linker and ADC construct

    Novel linker and ADC construct Glucuronidation site protected while bound to IgG Immunomedics’ ADC Platform With SN - 38 Goldenberg et al, Oncotarget (2015) 6:22496 - 512 • Linker coupled to 20 th position stabilizes lactone ring − pH dependent release • Glucuronidation site (10 th position) is prot

  19. Slide 19: Key Clinical Points

    Key Clinical Points 19 • Novel ADC platform designed to address the limitations of first - generation ADCs: Therapeutic index appears to be improved – Active metabolite of irinotecan, SN - 38, can be conjugated to mAbs and provides higher SN - 38 doses in blood and tumor (~130 - fold in animal studi

  20. Slide 20: Intellectual Property Highlights

    Intellectual Property Highlights 20 • Company has over 300 US and over 400 foreign patents • In a recent ranking of IP strength by the Patent Board, Immunomedics was ranked No. 4 innovator in the biotechnology industry • Company awarded Thomas A . Edison Award by Research & Development Council of Ne

  21. Slide 21: IMMU-132 Patent Portfolio

    IMMU - 132 Patent Portfolio 21 • 32 issued U.S. and 16 foreign patents covering composition of matter, synthesis and uses of IMMU - 132 • Company’s main composition of matter patents expire in 2023 in the U.S., and in 2029 in Europe – In addition, IMMU - 132 has patent coverage through 2033 for uses

  22. Slide 22: IMMU-132 Results in Urothelial Cancer

    IMMU - 132 – Results in Urothelial Cancer 22 Scott T. Tagawa, M.D., Richard A. Stratton Associate Professor in Hematology & Oncology; Medical Director, Genitourinary Oncology Research Program, Division of Hematology & Medical Oncology Weill Cornell Medical College, New York, NY

  23. Slide 23: Randomized Trials in Advanced Urothelial Carcinoma

    Randomized Trials in Advanced Urothelial Carcinoma Study Response Rate Overall Survival Comments Cisplatin vs MVAC Loehrer et al JCO 1992 11 vs 36% p < 0.0001 8.8 vs 12.5 mo p = 0.0002 MVAC became standard of care CisCA vs MVAC Logothetis et al JCO 1990 46 vs 65% p < 0.05 10.0 vs 12.6 mo p = 0.0003

  24. Slide 24: Kaplan-Meier Curves for Overall Survival with Cisplatin-based Chemotherapy

    Kaplan - Meier Curves for Overall Survival with Cisplatin - based Combination Chemotherapy von der Maase, H. et al. J Clin Oncol; 23:4602 - 4608 2005 24

  25. Slide 25: Relapsed/Refractory Metastatic Urothelial Cancer

    Relapsed/Refractory Metastatic Urothelial Cancer 25 1 - Bellmunt et al, J Clin Oncol 2009 2 - Petrylak D et al, J Clin Oncol 2016 3 - Rosenberg JE et al, Lancet 2016 TREATMENT ORR PFS OS Vinflunine 1 8.6% 3.0 mo 6.9 mo Docetaxel 2 8.9% 2.8 mo 9.2 mo Docetaxel + Ramucirumab 2 24% 5.4 mo 10.4 mo Atezo

  26. Slide 26: Antibody-Drug Conjugates

    Antibody - Drug Conjugates 26 • Antibody – Antigen characteristics – Antigen: Tumor specificity, expression – Antibody: Internalization, immunogenicity • Linker – Stability in circulation – Cleavable vs non - cleavable • Payload – Potency – Mechanism against tumor type Klute, Nackos et al; OncoTarge

  27. Slide 27: Phase I/II Clinical Trial (NCT01631552)

    Phase 1 IMMU - 132 - 01 Clinical Trial 1 (NCT01631552) 27 • Patients with metastatic treatment - refractory epithelial cancers • Treatment regimen: Days 1 and 8 every 21 days – Dose delays and reductions allowed to encourage treatment continuation – Treatment continued typically until progression or

  28. Slide 28: IMMU-132 in Advanced Refractory Urothelial Cancers: Best Response

    - 1 0 0 - 8 0 - 6 0 - 4 0 - 2 0 0 2 0 4 0 B e s t R e s p o n s e B e s t % c h a n g e i n T L f r o m b a s e l i n e C o m p le te re s p o n s e ( c o n f irm e d ) P a r t ia l r e s p o n s e ( c o n f ir m e d ) P a r t ia l r e s p o n s e ( p e n d in g ) P a r t ia l r e s p o n s e ( u n

  29. Slide 29: Duration of Response for PR + SD UBC patients

    IMMU - 132: Duration of Response for PR + SD UBC patients Urothelial Cancers 22/27 pts (81%) with SD or better response KM - derived median duration of response for pts with PR + SD (N = 22): Median = 8.1 mos (95% CI = 6.9, 14.6) Median time to 1 st objective response = 1.9 mos (range, 1.7 to 5.7 mo

  30. Slide 30: PFS and OS for Metastatic Urothelial Cancers

    IMMU - 132: PFS and OS for Metastatic Urothelial Cancers ITT = all 32 - treated patients Median PFS = 7.2 months (95% CI = 4.9, 10.7) Median OS = 15.5 months (95% CI = 10.5, 17.2) 30

  31. Slide 31: Case study

    Case study 31 • 2008: diagnosis high grade non - invasive UC bladder  transurethral resection, BCG • 2014 metastatic urothelial carcinoma to LN’s  gem/cis +/ - bevacizumab  gem/carbo • June, 2015 initiate IMMU - 132 Baselin e : Liver + L y mp h Node mets Com p l et e response in target lesio n s

  32. Slide 32: IMMU-132 in Urothelial Cancer: Conclusions

    IMMU - 132 in Urothelial Cancer: Conclusions • IMMU - 132 is a novel ADC with promising anti - tumor activity in relapsed/refractory metastatic urothelial carcinoma • Novel ADC platform designed to address the limitations of first - generation ADCs • Acceptable safety profile in heavily pretreated,

  33. Slide 33: IMMU-132 Results in NSCLC and SCLC

    IMMU - 132 – Results in Non - Small - Cell and Small - Cell Lung Cancers Ronald J. Scheff, M.D., Assistant Professor of Clinical Medicine, Weill Cornell Medical College; Medical Oncologist, New York - Presbyterian Hospital, New York, NY 33 Dra ft

  34. Slide 34: Relapsed/Refractory Metastatic Lung Cancers

    Relapsed/Refractory Metastatic Lung Cancers 34 • Lung Cancer is the most common deadly form of cancer – Annually accounts for ~ 1 . 3 million cancer deaths worldwide and ~ 160 , 000 in U . S . (More deaths than colorectal, prostate and breast cancers combined) – NSCLC (85%), SCLC (~15%) • 5 - year s

  35. Slide 35: Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

    Metastatic Non - Small - Cell Lung Cancer (mNSCLC) 35

  36. Slide 36: IMMU-132 in mNSCLC: Best Response

    IMMU - 132 in mNSCLC: Best Response By RECIST 1.1 47 response assessable; 45 with CT (8 and 10 mg/kg) ORR = 19% 64% had tumor shrinkage from baseline, including squamous pathology and prior immune checkpoint inhibitors Median duration of response: 8 months Clinical Benefit Rate (PR+SD > 4 mos) = 43%

  37. Slide 37: PFS and OS mNSCLC

    IMMU - 132: PFS and OS mNSCLC (8 or 10 mg/kg) ITT = all 54 - treated patients Median PFS = 5.2 months (95% CI = 2.6, 7.1) Median OS = 9.5 months (95% CI = 6.0, 16.7) 37

  38. Slide 38: IMMU-132 Benefit Versus Prior PD1/PD-L1 Therapy

    IMMU - 132 Benefit Versus Prior PD1/PD - L1 Rx Benefit 38 Age Sex # of Prior Tx CPI # line CPI Response to CPI Duration of CPI treatment (mos) IMMU - 132 Doses IMMU - 132 best response Best % change TL Histology PFS (mo) 78 M 2 Nivolumab 2 Yes 8 9 SD 0 SQ 1.2+ 63 F 6 Nivolumab 2 No 1 15 SD 7 AC 3.7+

  39. Slide 39: Metastatic Small-Cell Lung Cancer (mSCLC)

    Metastatic Small - Cell Lung Cancer (mSCLC) 39

  40. Slide 40: IMMU-132 in mSCLC: Best Response

    IMMU - 132 in mSCLC: Best Response By RECIST 1.1 8 and 10 mg/kg ORR = 16% 60% had tumor shrinkage from baseline Median Duration of Response (PR+SD): 5.2 months Clinical Benefit Rate (PR+SD > 4 mos) = 40% Median # prior therapy: 2 (range, 1 – 7) - 1 0 0 - 8 0 - 6 0 - 4 0 - 2 0 0 2 0 4 0 6 0 8 0 B e s

  41. Slide 41: PFS and OS for mSCLC

    IMMU - 132: PFS and OS for mSCLC (8 or 10 mg/kg) ITT = all 53 - treated patients Median PFS = 3.7 months (95% CI = 2.0, 4.3) Median OS = 7.0 months (95% CI = 5.5, 8.3) 41

  42. Slide 42: Lung Cancer: Adverse Events in Study Population

    IMMU - 132 in Lung Cancer (NSCLC + SCLC): Adverse Events in Study Population (Regardless of Causality) 42 All Grades Grades ≥3 Adverse Event n % n % Nausea 70 65% 5 5% Diarrhoea 61 57% 9 8% Fatigue 50 47% 10 9% Neutropenia 43 40% 33 31% Vomiting 37 35% 2 2% Alopecia 33 31% 0 0% Anaemia 31 29% 5 5% C

  43. Slide 43: Case Study: NSCLC, confirmed PR

    • 82 year old male initially diagnosed with NSCLC July 2012 (EGFR and ALK negative) • Prior therapies: 43 – Carboplatin – Abraxane – Ge m ci t abi ne – Carboplatin – Etoposide – Erlotinib – Vinorelbine (Jul - Nov 2012)/pemetrexed (Jul 2012 - Apr 2013) (May - Aug 2013) (Aug - Dec 2013 ) (Dec 2013 - A

  44. Slide 44: NSCLC: Partial Response

    Patient xxx - 035 (NSCLC): Partial Response Baseline 09 Dec 2014 Target lesion 1: Rt lower lobe, 48 mm 1 st Assessment: 09 Feb 2015 Target lesion 1: Rt lower lobe, 40 mm Baseline Target Lesions 3 (liver) and 4 (LN) Da e: 9Dec 2014 Assessment 3: Confirmed PR Target Lesions 3 (liver) and 4 (LN); 09 Ma

  45. Slide 45: Case Study: SCLC, confirmed PR

    Case Study: SCLC, confirmed PR (PFS = 7.9 mos) 45 • 73 year old female initially diagnosed with SCLC July 2013 • Prior therapy – Carboplatin + Etoposide (6 cycles; Oct 2012 – Jan 2013); 11 - month response – Topotecan (Sep – Dec 2013); No response – Carboplatin + Etoposide (6 cycles; Nov 2013 – Apri

  46. Slide 46: SCLC: Partial Response

    Patient 255 - 012 (SCLC): Partial Response Rt Lower Lobe Lt Axillary mass liver mass w i th Lt adrenal mass liver mass in view Responses in 4 of the 5 target lesions are shown Top row is baseline, bottom row is 1 st response assessment 8 weeks after treatment start 46

  47. Slide 47: IMMU-132 in Lung Cancer: Conclusions

    IMMU - 132 in Lung Cancer: Conclusions 47 • >50 patients enrolled to - date in each of NSCLC and SCLC • Patients very advanced (stage IV) and heavily pretreated, including having immune checkpoint inhibitors • Patients with either tumor showed ~60% shrinkage from baseline when treated with IMMU - 13

  48. Slide 48: IMMU-132 Results in Triple-Negative Breast Cancer

    IMMU - 132 – Results in Triple - Negative Breast Cancer 48 Linda T. Vahdat, M.D., MBA, Professor of Medicine, Weill Cornell Medical College; Co - Leader BC Program at Meyer Cancer Center, New York, NY

  49. Slide 49: Triple-Negative Breast Cancer Facts

    Triple - Negative Breast Cancer Facts: 49 • ~15% of all breast cancer diagnosed • No optimal standard therapy in the adjuvant or metastatic setting • Metastatic TNBC – Median survival ~12 months – Short PFS - ~1.7 to 3.7 months • Large unmet need in the breast cancer community

  50. Slide 50: Typical Clinical Scenario For Metastatic TNBC

    N= 518 TNBC pts Setting: 0 - 1 prior lines of therapy Typical Clinical Scenario For Metastatic TNBC 50

  51. Slide 51: IMMU-132 in mTNBC: Prior Therapy and Sites of Disease

    Number of prior therapies – median (range) 5 (2 - 12) Prior chemotherapy drugs (>10%) Taxanes 67 (97%) Cyclophosphamide 63 (91%) Anthracyclines 58 (84%) Platinum agents 48 (70%) Fluoropyrimidine agents 34 (49%) Gemcitabine 30 (43%) Eribulin 27 (39%) Vinorelbine 13 (19%) Ixabepilone 8 (12%) Sites of

  52. Slide 52: IMMU-132 in mTNBC: Best Radiographic Response

    IMMU - 132 in mTNBC: Best Radiographic Response* ORR (25/85) = 29.4% • 2 CR (confirmed) • 23 PR (confirmed) • 3 PR (confirmatory CT pending) • 33 Stable Disease (10 pts ≥ 20% SD) • 21 progressive disease • 3 lack TL measurement at this time • 3 inevaluable for response; had 2 - 3 doses, but withdrew

  53. Slide 53: Duration of Response for CR+PR TNBC patients

    IMMU - 132: Duration of Response for CR+PR TNBC patients > 2 Prior Lines for Metastatic Disease, Completed 1 Cycle 10 mg/kg • For 25 pts with CR+PR: • Median duration of response = 10.8 mos (95% CI = 6.8, 12.7 mos) • Median time to 1 st response = 2.1 mos (range, 1.6 to 13.4 mos) • For 61 pts with C

  54. Slide 54: Progression-free Survival and Overall Survival in mTNBC

    IMMU - 132 in mTNBC*: Progression - free Survival and Overall Survival *For patients with TNBC, > 2 Prior Therapy Lines for Metastatic Disease, 10 mg/kg ITT = all 89 - treated patients Median PFS = 6.0 months (95% CI = 5.0, 7.1) Median OS = 18.8 months (95% CI = 11.5, 20.6) 56

  55. Slide 55: IMMU-132 in mTNBC: Adverse Events

    IMMU - 132 in mTNBC: Adverse Events in Study Population (Regardless of Causality) 57 All Grades Grades ≥3 Adverse Event n % n % Nausea 51 74% 5 7% Neutropenia 47 68% 27 39% Diarrhea 41 59% 9 13% Anemia 38 55% 10 14% Vomiting 35 51% 7 10% Fatigue 35 51% 6 9% Alopecia 31 45% 0 0% Constipation 26 38% 1

  56. Slide 56: Dramatic Response in Chest Wall Disease to IMMU-132

    Dramatic Response in Chest Wall Disease to IMMU - 132 Before treatment with IMMU - 132 After 2 cycles of IMMU - 132 58 y.o. with Stage 2 TNBC diagnosed in 2011 (ACTdd). Recurred in 2014 with an IBTR ( Tcarbo). CW nodules 3/2015: received Ixabepilone+ xeloda, eribulin, casodex ( AR+). 58

  57. Slide 57: TNBC Case Study: Partial Response (24.1 months)

    TNBC Case Study: Partial Response (24.1 months) 59 • 52 yo female diagnosed Nov 2004 with stage I breast cancer. • Chemotherapy history – Doxorubicin/Cytoxan/Paclitaxel (Jan – Jun 2005) – Tamoxifen (Jun – Aug 2005) – Anastrozone followed by Letrozole (Sep 2005 – Apr 2006) – Capecitabine (Aug 2011 –

  58. Slide 58: TNBC Patient Response Imaging

    Patient xxx - 010: TNBC TL #1 TL #1 Baseline: 28Jul14 60 1 st assessment: 22Sep14 Baseline: 28Jul14 1 st assessment: 22Sep14 8 - week assessment: - 51% decrease in index lesions TL #2 TL #2

  59. Slide 59: IMMU-132 in mTNBC: Conclusions

    IMMU - 132 in mTNBC: Conclusions 61 • In advanced, heavily pre - treated TNBC patients IMMU - 132 is very active: – Confirmed Response Rate ( CR+PR) = 29.4% with CBR (+SD≥6mos) = 44% – Median progression - free survival = 6 months – Median overall survival = 18.8 months • IMMU - 132 has a good thera

  60. Slide 60: IMMU-132 Preclinical Development (PARP/Chemo Combinations)

    IMMU - 132 – Preclinical Development (PARP/Chemo Combinations) 62 Thomas Cardillo, Ph.D., Executive Director, Preclinical and Hybridoma Development

  61. Slide 61: Antitumor Activity of IMMU-132 Alone and Combined with Chemotherapy

    Antitumor Activity of IMMU - 132 Alone and Combined with Chemotherapy 63 • Preclinically, IMMU - 132 has demonstrated efficacy against a wide range of Trop - 2 - expressing solid tumors (e.g., NSCLC, TNBC, pancreatic, gastric, colon, and urinary bladder) • In TNBC tumor - xenografts, when IMMU - 132

  62. Slide 62: Tumor Growth Inhibition of IMMU-132 and Olaparib in TNBC Models

    Tumor Growth Inhibition of Combined IMMU - 132 and Olaparib in Human TNBC Models: BRCA1/2 - and PTEN - Defective Tumors 0 . 0 0 0 . 7 5 1 . 0 0 1 . 2 5 O la p a r ib ( 5 0 m g / k g ) C o n t r o l A D C ( 2 5 0  g ) S a l i n e 0 7 1 4 2 1 2 8 3 5 4 2 4 9 5 6 6 3 T im e P o s t - T u m o r T ra n

  63. Slide 63: Summary of in vitro and in vivo IMMU-132 combinations

    Summary of in vitro and in vivo results of IMMU - 132 combinations with various chemotherapeutics in human TNBC 65 Chemotherapeutic In Vitro Synergy with IMMU - 132 In Vivo Combination Superior to M o no t h e r a p y PARP Inhibitors Ol a p a r ib * Yes † Yes T a l a z oparib * Yes ‡ Yes Ru c aparib

  64. Slide 64: Summary and Conclusions

    Summary and Conclusions 66 • By inhibiting topoisomerase I with IMMU - 132 combined with PARP inhibition, synergistic growth inhibition is achieved in both BRCA1/2 defective cells as well as in cells with wild - type expression, including one with only a PTEN defect – This suggests that IMMU - 132 m

  65. Slide 65: IMMU-132 Competitive Landscape and Commercial Assessment

    IMMU - 132 – Competitive Landscape and Commercial Assessment 67 Andrew Funderburk, Partner, and Earl Gillespie, Consultant, Health Advances

  66. Slide 66: Q&A Session

    Q&A Session 68

  67. Slide 67: IMMU-132 Manufacturing / Regulatory / Development Plan for TNBC

    IMMU - 132 Manufacturing / Regulatory / 69 Development Plan for TNBC Edmund Rossi, Ph.D., Associate Vice President, Process Development and Manufacturing

  68. Slide 68: Phase 3/Commercial Production of IMMU-132

    Phase 3/Commercial Production of IMMU - 132 BSP Conjugation Fill and L y oph i li z a t i on 200 mg/vial JMPS CL2A - SN - 38 IMMU hRS7 - 80 - 36 - 35 IgG 70

  69. Slide 69: IMMU-132 Manufacturing Timeline

    IMMU - 132 Manufacturing Timeline L o t 71 2016 Q2 2016 Q3 2016 Q4 2017 Q1 2017 Q2 2017 Q3 2017 Q4 I g G S N 38 DP I M MU Eng (2.4 kg) I0 E M fg C omp S ta b ili ty → Clin (2.4 kg) I1 1 M fg Rel Clin (2.4 kg) I2 1 , 2 M fg Rel C omp S ta b ili ty → Clin (2.4 kg) I3 2 M fg Rel Clin (2.4 kg) I4 4 M f

  70. Slide 70: Regulatory Status Update

    Regulatory Status Update 72 Designations Indication Breakthrough Fast Track Orphan Accelerated Approval TNBC x x Planned UC Pending Submission SCLC Pending Submission * x x NSCLC Pending Submission x Pancreatic x Regulatory Progress ▪ Received Scientific Advice from the EMA on confirmatory Phase 3 p

  71. Slide 71: IMMU-132: Regulatory Activities Timeline

    IMMU - 132: Regulatory Activities Timeline 73 2016 Q4 2017 Q1 2017 Q2 2017 Q3 2017 Q4 2018 Q1 3 - Month repeat - dose monkey toxicology study Study Period Nonclinical & Clinical P h arma c ol o gy EOP2 meeting  CMC EOP2 Meeting  Initial Scientific Advice Meeting for Nonclinical and Quality Discipl

  72. Slide 72: IMMU-132: Updated Clinical Development in TNBC

    • Single - arm Phase 2 Basket (diverse cancers) study – Enrolled 100 assessable TNBC patients with at least 2 prior therapies required for BLA submission – Patient follow - up continuing – Third - party “blinded” confirmation of response assessment ongoing – high concordance to - date • Phase 3 conf

  73. Slide 73: Phase 3 Confirmatory Trial Design for IMMU-132: TNBC

    Phase 3 Confirmatory Trial Design for IMMU - 132: TNBC ▪ Primary endpoint is PFS ▪ Two arms: IMMU - 132 vs physician’s choice of 1 from 4 chemotherapies ▪ 328 patients to be enrolled, 1:1 randomization Designed to Replicate Success Attention to Execution ▪ Trial will be conducted under a SPA and is

  74. Slide 74: IMMU-130, Epratuzumab, Veltuzumab, Milatuzumab and IMMU-114

    IMMU - 130, Epratuzumab, Veltuzumab, Milatuzumab and IMMU - 114 William A. Wegener, M.D., Ph.D., Chief Medical Officer 76

  75. Slide 75: IMMU-130 (labetuzumab govitecan) Mechanism of Action

    IMMU - 130 (labetuzumab govitecan) 77 Mechanism of Action • IMMU - 130 binds CEACAM5 on colorectal tumors and other cancers • IMMU - 130 releases SN - 38 locally and internally for diffusion into cancer cells

  76. Slide 76: Phase 1/2 Trial of IMMU-130 in Metastatic Colorectal Cancer

    Phase 1/2 Trial of IMMU - 130 in Patients with Refractory/Relapsing Metastatic Colorectal Cancer 78 • Multicenter study – Richard Goldberg, OSU Cancer Center, Columbus, OH – Steven Cohen, E. Dotan, Fox Chase Cancer Center, Philadelphia, PA – Wells Messersmith, C. Lieu, U. Colorado Cancer Center, Aur

  77. Slide 77: IMMU-130 Treatment Response by RECIST 1.1

    PR n(%) Median PFS (mo.) Median OS (mo.) 8 mg/kg QW (n = 16) 0 4.8 7.5 10 mg/kg QW (n = 15) 0 4.6 9.2 4 mg/kg BIW (n = 18) 0 2.1 6.0 6 mg/kg BIW (n = 16) 1 (6%), confirmed 3.7 7.3 Regorafenib (3 rd line) 1% 2.0 6.4 Treatment Response by RECIST 1.1 (AACR 2015) • Partial response (88% shrinkage of lun

  78. Slide 78: Humanized B-cell Antibodies

    Humanized B - cell Antibodies 8 0 • Epratuzumab (anti - CD22) • Veltuzumab (anti - CD20)

  79. Slide 79: Epratuzumab (hLL2)

    Epratuzumab (hLL2) 81 • CD22 expressed across different NHL histologies, and pediatric/adult ALL • High affinity binding to CD22 (0.7 nM) induces rapid CD22 internalization • May block natural ligands and elicit signals which leads to inhibition of BCR • Induces phosphorylation of cytoplasmic tail o

  80. Slide 80: Epratuzumab/Rituximab Combination Studies

    Epratuzumab/Rituximab Combination Studies (N=136) 82 Study Design Population Treatment Pts 128 Singl e - Ce nt er Refractory or Recurrent NHL 360 mg/m 2 hLL2 followed by 375 mg/m 2 rituximab once weekly for 4 doses 22 138 Multi - Ce nt er Recurrent or Refractory NHL 360 mg/m 2 hLL2 followed by 375 m

  81. Slide 81: E/R Combination Response Rates

    E/R Combination Response Rates 83 Study Population OR CR/CRu Single - Center #128 1 FCL (N=15) 67% 60% Multi - Center #138 2 FCL (N=41) 61% 24% Multi - Center #08EU 3 FCL (N=33) 64% 24% Rituximab Phase 2* FCL (N=60) 38% 10% Rituximab Phase 2* FCL/SLL (N=166) 48% 6% Single - Center #128 1 DLBCL (N=5)

  82. Slide 82: IntReALL Study in Pediatric Relapsed ALL

    IntReALL Phase 3 Study of Chemotherapy with or without Epratuzumab in Pediatric Relapsed ALL 8 8 4 4 • EU, Berlin - based consortium • Long - term randomized study • Target enrollment 612 patients • 4 - year planned accrual period • Primary endpoint PFS at 4 years • Study currently continuing Cooper

  83. Slide 83: Veltuzumab: Oncology and Autoimmune Markets

    Veltuzumab: Oncology and Autoimmune Markets 85 • 2 nd generation anti - CD20 antibody • Structural differences from rituximab* – Humanized antibody (rituximab is chimeric) – Binding site differs from rituximab by one amino acid in VH - CDR3, and has different framework regions • Functional differenc

  84. Slide 84: Veltuzumab: NHL IV Phase 1/2 Trial

    Veltuzumab: NHL IV Phase 1/2 Trial • 82 patients • Adults CD20 + B - cell NHL, failed ≥1 prior therapy • Veltuzumab infusions once weekly X 4 wks • 5 Dose levels: 80, 120, 200, 375, 750 mg/m 2 • Rapid infusions & limited mild moderate reactions • No other significant safety issues • Treatment respon

  85. Slide 85: Veltuzumab ITP Phase Study

    Veltuzumab ITP Phase 1 Study • 41 Adults with relapsed ITP (32 chronic ITP > 1 yr) • Veltuzumab 80 - 320 mg, 2 doses, 2 weeks apart • 7 patients IV, 34 patients SC • 16 additional pts received 320 mg SC, weekly x 4 • Limited mild - moderate injection reactions, no other safety issues • Durable plate

  86. Slide 86: Veltuzumab Conclusions

    Veltuzumab Conclusions 88 • Anti - CD20 market well established including autoimmune indications • Preclinical evidence of superiority (binding duration, in vivo efficacy) vs. rituximab: lower dose potent clinically • Promising clinical experience in > 200 patients, oncology and autoimmune • Improve

  87. Slide 87: Humanized Antigen-Presenting Cell Antibodies

    Humanized Antigen - Presenting Cell Antibodies 89 • Milatuzumab (anti - CD74) • IMMU - 114 (anti - HLA - DR)

  88. Slide 88: IMMU-115 (Milatuzumab)

    IMMU - 115 (Milatuzumab) 90 • Targets CD74 on antigen - presenting cells (APC), including B - cells and dendritic cells • Clinical and pharmacodynamic activity in heme malignancies – Alone (Kaufman et al, Br J Haematol. 2013 163:478 - 86) and combined with anti - CD20 veltuzumab (Christian et al. Br

  89. Slide 89: SC IMMU-115 Safety and Efficacy in SLE

    SC IMMU - 115 Appears Safe with Evidence of Treatment Efficacy in SLE • All 10 patients decreased initial disease activity in at least one body system • Suppression of disease activity extended 24 weeks in most patients • Injection reactions were mild - moderate • No other safety issues emerged • As

  90. Slide 90: IMMU-114 – 2nd Generation anti-HLA-DR antibody

    IMMU - 114 – 2 nd Generation anti - HLA - DR antibody • Human Leukocyte - Antigen - DR (HLA - DR) - appealing target for therapy – Significantly higher expression than CD20 and other typical B - cell markers in NHL, CLL, other hematologic malignancies – Also expressed in solid tumors (e.g., melanoma

  91. Slide 91: IMMU-114 – Initial Phase 1 Study

    IMMU - 114 – Initial Phase 1 Study • Initial study in relapsed/refractory NHL and CLL after failing rituximab - containing therapies is showing encouraging efficacy with no severe reactions as seen previously (ClinicalTrials.gov, NCT01728207) • Results recently presented at Pan Pacific Lymphoma Conf

  92. Slide 92: IMMU-140 – Overview

    IMMU - 140 – Overview Thomas Cardillo, Ph.D., Executive Director, Preclinical and Hybridoma Development 94

  93. Slide 93: Antitumor Activity of IMMU-140 in ALL, AML, MM, and CLL Models

    Antitumor Activity of IMMU - 140 in ALL, AML, MM, and CLL Hematopoietic Disease Models 95 • IMMU - 140 makes use of the same CL2A - SN - 38 conjugation methodology as used for IMMU - 132 to attach 6 - 8 SN - 38 molecules per IMMU - 114 molecule • IMMU - 140 provides an added benefit of a dual - ther

  94. Slide 94: IMMU-140 survival data

    0 1 4 2 8 4 2 5 6 7 0 8 4 9 8 1 1 2 0 2 5 5 0 7 5 1 0 0 S a l i n e IM M U - 1 1 4 ( 5 0 0  g ) C o n t r o l Ig G ( 5 0 0  g ) C o n t r o l A D C ( 5 0 0  g ) IM M U - 1 4 0 vs . c o n tr o ls ( P - v a l u e ) 3 7 d a y s < 0 . 0 0 0 1 M e d ia n S u rv iv a l 6 6 . 5 d a y s n . a . 2 3 d a y

  95. Slide 95: Therapeutic Efficacy of IMMU-140 versus IMMU-114 in Mouse Model

    0 1 4 2 8 9 8 1 1 2 1 2 6 1 4 0 0 2 5 5 0 7 5 1 0 0 M e d ia n C o m p a ra b le IM M U - 1 4 0 vs . 4 2 5 6 7 0 8 4 T im e ( D a y s ) P e r c e n t S u r v i v a l i . v . C e lls I n je c t e d T h e r a p y S u rv iv a l IM M U - 1 1 4 IM M U - 1 4 0 ( 5 0 0  g ; i . p . ) > 1 3 3 d a y s n . a

  96. Slide 96: IMMU-140 Conclusions

    • IMMU - 140 provides an added benefit of a dual - therapeutic through the direct antitumor activity mediated by the IMMU - 114 HLA - DR - binding moiety (p - ERK1/2 and AIF signaling) and the added cytotoxic effect of SN - 38 delivery to the cells (caspase cascade and PARP cleavage) • IMMU - 140 an

  97. Slide 97: Bispecific Antibodies and Immuno-Oncology Programs

    Bispecific Antibodies and Immuno - Oncology Programs 99 Edmund Rossi, Ph.D., Associate Vice President, Process Development and Manufacturing

  98. Slide 98: Bispecific Antibodies Platform Technology

    Bispecific Antibodies Platform Technology 100 • Dock - and - Lock® (DNL®) for improved therapy of cancers and immune diseases • DNL BsMabs for immuno - oncology (T - cell retargeting for solid cancer therapy)

  99. Slide 99: Dock-and-Lock Proprietary Technology

    AD2 = C G QIEYLAKQIVDNAIQQA G C ( AKAP - IS : 0.4 nM) DDD2 = C GHIQIPPGLTELLQGYTVEVLRQQPPDLVEFAVEYFTRLREARA (DDD - RII  ) 101 Dock - and - Lock® Proprietary Technology

  100. Slide 100: Features of DNL

    Features of DNL  102 • One of the two modules is always present in two copies • The method is modular and versatile • Ease of preparation • Site - specific conjugation • Quantitative yields • Homogeneous final product of defined composition, retained bioactivities of each parental module, and in vi

  101. Slide 101: 22*-(20)-(20) Bispecific Antibody

    22* - (20) - (20) (PLoS ONE 2014, 9: e98315) Ep r a t u z u m a b 103 Veltuzumab V eltuzum a b The conjugation of Fab - DDD2 to C L - AD2 - IgG retains a fully functional Fc

  102. Slide 102: 22*-(20)-(20) Potently Kills Daudi Cells, But Not Normal B Cells

    22* - (20) - (20) Potently Kills Daudi Cells, But Not Normal B Cells 104

  103. Slide 103: Potential Indications for CD22-CD20 Targeting

    Potential Indications for CD22 - CD20 Targeting 105 • B - cell non - Hodgkin lymphomas (FL and DLBCL), chronic lymphocytic leukemia, acute lymphoblastic leukemia (children) • B - cell - related autoimmune diseases: rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, psoriasis, gr

  104. Slide 104: Trivalent Bispecific Antibodies for Redirected T-Cell Killing

    C L C L C C H 1 H 1 V L V V H L V H DDD2 DDD2 H H H H H H AD2 Okt 3 s c F v - A D 2 DNL (19) - 3s 106 Trivalent Bispecific Antibodies (Fab) 2 x scFv for Redirected T - Cell Killing hA19 - Fab - DDD2

  105. Slide 105: Bispecific Antibodies for T-cell Retargeting Immunotherapy

    Bispecific Antibodies for T - cell Retargeting Immunotherapy 107 • CD19 target for lymphomas and leukemias • Trop - 2 target for solid cancers • CEACAM5 target for solid cancers

  106. Slide 106: (X)-3s Bispecific Antibodies Redirect T-cells to Bind Cancer Cell

    (X) - 3s Bispecific Antibodies Redirect T - cells to Bind Cancer Cell 108 and Kill Cancer Cells T T T T ( X ) - 3s

  107. Slide 107: (X)-3s Bispecific Antibodies Redirect T-cells to Bind and Kill Cancer Cells

    (X) - 3s Bispecific Antibodies Redirect T - cells to Bind and Kill Cancer Cells 109

  108. Slide 108: (X)-3s Mediate Potent Redirected T-cell Lysis of NHL Cells

    Da u d i - 8 100 90 80 70 60 50 40 30 20 10 0 - 1 3 ( 22 ) - 3s ( 19 ) - 3s ( 20 ) - 3s - 12 - 11 - 10 - 9 Log Concentration (M) % S p eci f ic L ysis Rossi et al, MAbs, 2014; 6(2):381 - 91 110 (X) - 3s Trivalent Bispecific Antibodies Mediate Potent Redirected T - cell Lysis of NHL Cells in an ex -

  109. Slide 109: (19)-3s Effective T-cell Therapy of Burkitt Lymphoma Xenografts

    Each regimen significantly inhibited tumor growth; >60% of mice were tumor - free at the end of the study 111 (19) - 3s Mediated Effective T - cell Therapy of Human Burkitt Lymphoma Xenografts (Raji) at Three Dosing Schedules

  110. Slide 110: (E1)-3s: Bispecific Antibody for Solid Cancers

    (E1) - 3s: A Bispecific Antibody for T - Cell Redirected Killing of Various Solid Cancers 112 • (X) - 3s design produced with DNL  – Bivalent binding of Trop - 2 on many types of human epithelial cancers • Potent activity with reduced cytokine release – Potentially allowing for higher dose with les

  111. Slide 111: (E1)-3s Targets T-cells to Trop-2 Solid Cancer Cells

    NCI - N87 Gastric Carcinoma Cells (green) CD8 + T Cells ( y ell o w / o r a n g e) (E1) - 3s (E1) - 3s (19) - 3s TF12 (19) - 3s Binds T cells but not tumor 113 TF12 Anti - Trop - 2 bsAb binds tumor, but not T cells Rossi et al, Mol Cancer Ther, 2014; 13(10):2341 - 51 (E1) - 3s Effectively Targets T

  112. Slide 112: (E1)-3s Killing of Pancreatic and Gastric Cancer Xenografts

    0 1 4 2 8 8 4 9 8 0 2 5 5 0 7 5 1 0 0 4 2 5 6 7 0 T im e ( D a y s ) P e r c e n t S u r v i v a l 9 8 1 1 2 1 2 6 0 2 5 5 0 7 5 1 0 0 ( E 1 ) - 3 s + P E G A S Y S ( E 1 ) - 3 s P E G A S Y S U n t re a te d 0 1 4 2 8 4 2 5 6 7 0 8 4 T im e ( D a y s ) P e r c e n t S u r v i v a l • Low doses (50

  113. Slide 113: (X)-3s Design Less Likely to Induce Cytokine Release Syndrome

    - 1 2 - 9 0 500 1000 1500 - 11 - 10 log [bsAb], M [ I L - 6 ] , pg / m L - 1 2 - 9 0 500 1000 1500 2000 [ I L - 2 ] , pg / m L - 1 2 - 9 0 250 500 750 1000 - 11 - 10 log [bsAb], M [ TNF -  ] , p g / m L - 11 - 10 log [bsAb], M IFN -  - 1 2 - 9 0 20000 40000 60000 1250 80000 - 11 - 10 log [bsAb], M

  114. Slide 114: (E1)-3s Redirects T-cell Killing of Breast and Prostate Cancers

    (E1) - 3s Effectively Redirects T - cell Killing of Breast (including TNBC) and Prostate Cancers - 1 3 - 9 - 8 0 2 0 4 0 6 0 8 0 1 0 0 - 1 2 - 1 1 - 1 0 lo g [ ( E 1 ) - 3 s ] , M % U n t r e a t e d M D A - M B - 2 3 1 ( T N B C ) H C C 3 8 ( T N B C ) B T - 2 0 ( T N B C ) H C C 1 9 5 4 ( B r e a

  115. Slide 115: (E1)-3s Killing of TNBC Xenografts with Checkpoint Inhibitor

    (E1) - 3s Effectively Mediated T - cell Killing of Triple - negative Breast Cancer Xenografts, which was Enhanced with a Checkpoint Inhibitor Antibody 0 6 3 0 2 5 5 0 7 5 O u t - G ro w th C o n tro l ( M D A - M B - 2 3 1 c e ll o n ly ) U n tre a te d C o n tro l ( T u m o r c e lls + T c e lls )

  116. Slide 116: T-cell Retargeting Conclusions

    • (E1) - 3s effectively induced T - cell - mediated killing of Trop - 2 - expressing pancreatic, gastric, colorectal, prostate and breast cancer cells ( in vitro and in vivo results) • Reduced cytokine release and potentially reduced side effects • IFN - α potentiates retargeted T - cell killing of

  117. Slide 117: Concluding Remarks

    Concluding Remarks David M. Goldenberg, Sc.D., M.D., Chairman, Chief Scientific Officer, and Chief Patent Officer 119

  118. Slide 118: Key Programs

    Key Programs 120 • New ADC technology using a moderately toxic drug conjugated at a high drug:antibody ratio – IMMU - 132 : TNBC, UBC, NSCLC, SCLC, followed by other metastatic breast cancers, metastatic endometrial and prostate cancers – IMMU - 130: CRC and other CEA - expressing cancers (head - an

  119. Slide 119: Key Programs (cont'd)

    Key Programs (cont’d) 121 • Unconjugated humanized antibodies – Epratuzumab, veltuzumab, milatuzumab, IMMU - 114 • Immuno - Oncology – Bispecific antibody T - cell retargeting (Trop - 2 and CEACAM5 targets for solid cancers) – Combination agents including alpha - interferon and immune checkpoint inh

  120. Slide 120: How Can We Further Improve IMMU-132 Results?

    How Can We Further Improve IMMU - 132 Results? 122 • Overcome tumor resistance • Modify therapy to include maintenance schedules and earlier treatment settings • Combination therapies: Immuno - oncology; PARP inhibitors; DNA - modifiers IMMUNOMEDICS SCIENTISTS ARE ADDRESSING THESE IMPORTANT GOALS AN

  121. Slide 121: Thank You

    Thank You 123 We hope you share our commitment to excellence in science as the basis for creating and advancing novel therapies in challenging diseases with unmet therapeutic needs

  122. Slide 122: Q&A Session

    Q&A Session 124

Immunomedics — Investor Day (January 2017) on 6ix